Examkin

Soru

Zorluk: OrtaInfectious Diseases

Match each clinical presentation of an immunocompromised patient with HIV to the most appropriate initial targeted antimicrobial regimen.

  • A 32-year-old man with a CD4 count of 45 cells/mm³ presenting with decreased visual acuity, floaters, and yellow-white retinal exudates with associated hemorrhage.Valganciclovir
  • A 45-year-old man with a CD4 count of 90 cells/mm³ presenting with new-onset seizures, focal left-sided weakness, and multiple ring-enhancing lesions with surrounding edema on brain MRI.Sulfadiazine, pyrimethamine, and leucovorin
  • A 35-year-old man with a CD4 count of 150 cells/mm³ presenting with a 3-week history of dry cough, exertional dyspnea, hypoxemia, and bilateral ground-glass opacities on high-resolution chest CT.Trimethoprim-sulfamethoxazole
  • A 38-year-old man with a CD4 count of 80 cells/mm³ presenting with subacute headache, fever, lethargy, and cerebrospinal fluid analysis showing an elevated opening pressure and encapsulated yeast on India ink stain.Amphotericin B and flucytosine

Cevap

Cytomegalovirus retinitis is treated with valganciclovir. Toxoplasma encephalitis is treated with sulfadiazine, pyrimethamine, and leucovorin. Pneumocystis jirovecii pneumonia is treated with trimethoprim-sulfamethoxazole. Cryptococcal meningitis is treated with amphotericin B and flucytosine.
Each clinical scenario correctly aligns a classic opportunistic infection presentation with its established first-line therapeutic regimen. CMV retinitis is managed with valganciclovir. Toxoplasmosis requires sulfadiazine and pyrimethamine. PCP is effectively treated with high-dose trimethoprim-sulfamethoxazole. Cryptococcal meningitis induction mandates amphotericin B and flucytosine.

Adım Adım Çözüm

1
Analyze the CD4 count and specific clinical manifestations for each patient to identify the underlying opportunistic pathogen.
Pathogens identified: Cytomegalovirus, Toxoplasma gondii, Pneumocystis jirovecii, and Cryptococcus neoformans.
Accurate identification of the specific opportunistic infection is an essential prerequisite for selecting the appropriate targeted antimicrobial therapy.
2
Determine the guideline-directed first-line pharmacological treatment for each identified infection.
Matched therapies: Valganciclovir for CMV; Sulfadiazine/pyrimethamine/leucovorin for Toxoplasma; TMP-SMX for PCP; Amphotericin B/flucytosine for Cryptococcus.
Standard of care requires these specific regimens to maximize efficacy, ensure CNS penetration where necessary, and minimize disease progression.
3
Pair each clinical vignette with its corresponding treatment regimen.
All four clinical presentations are successfully matched to their respective first-line therapies.
To synthesize the clinical diagnostic findings with the correct pharmacological management.

Anahtar Kavram

Targeted treatment of opportunistic infections in HIV/AIDS based on characteristic clinical presentations and specific CD4 count thresholds.
Bu soruyu puanla

Konular

Infectious Diseases

Bu konudan daha fazla soru